Ultrasound Guided Intra-sacroiliac Joint Injection: Methylprednisolone Versus Triamcinolone

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Intra-articular steroids have been also practiced since a long time. These agents have a better and safer profile as compared to oral drugs in terms of adverse effects/contraindications of the later. Moreover, Intra-articular steroids impart a better pain relief by delivering and also delays any surgical intervention thereby improving the patient's quality of life.

Without imaging, intra-articular injection has been shown in only 22% of patients so ultrasound, fluoroscopic imaging and computerized tomographic (CT) are required to ensure accuracy. Comparing to other guidance, ultrasound guided injection provides easy, safe, accurate, non-invasive, inexpensive imaging and lacking exposure to radiation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University

Criteria

Inclusion Criteria:

• Age between 50 - 70 years of both gender,

• sacroiliac pain with at least 3 of the 5 provocative tests are positive,

• pain did not relieved by the conservative therapy (rest, ice/heat, topical menthol, lidocaine patch, pelvic belt, physical therapy and NSIAD) for 4 weeks,

• positive diagnostic test 2 ml lidocaine 2% intra-articular SIJ injection one day before the procedure are included in this study.

Exclusion Criteria:

• The exclusion criteria are patient refusal,

• history of immunosuppression diseases,

• bleeding or coagulation disorders,

• sacroiliac pain of multiple sources,

• local skin infection,

• septic joint, osteomyelitis,

• renal patients (Serum Creatinine >1.8 ),

• decompensated liver diseases,

• local malignancy,

• psychiatric disorders affecting co-operation,

• previous history of chronic opioid use,

• intra articular sacroiliac injection within previous three months,

• negative diagnostic test,

• allergy or hypersensitivity to any of the study medications

• diabetes mellitus, type II with history of poor glycemic control

• morbid obesity ( BMI> 40 ).